Merck Sharp & Dohme (MSD) has said that its COVID-19 antiviral pill, molnupiravir, reduced the risk of hospitalization or death in a phase 3 clinical trial with no safety concerns, in comparison with the placebo group.

The company further stated that it has provided the relevant data as requested to help the DCGI ascertain the most appropriate use of the drug in the country. The statement came after the Indian Council of Medical Research (ICMR) did not include molnupiravir in the national COVID treatment protocol owing to safety concerns.

The company said that the drug has yet to be evaluated against Omicron variant in clinical studies, but it is known to interrupt the replication of SARS-CoV-2 and the clinical data have shown consistent efficacy across patients infected with different variants of concern. The company stated that preliminary preclinical data showed antiviral activity against Omicron, adding that the drug has the potential to become a critical tool for healthcare professionals and suitable patients… (ET Healthworld, January 7, 2022)